22 results
8-K
EX-2.1
AMGN
AMGEN Inc.
12 Dec 22
This Announcement Is Being Made Pursuant to Rule 2.7 of the Irish Takeover Rules
7:32am
8-K
EX-2.2
AMGN
AMGEN Inc.
12 Dec 22
This Announcement Is Being Made Pursuant to Rule 2.7 of the Irish Takeover Rules
7:32am
8-K
EX-2.1
AMGN
AMGEN Inc.
4 Aug 22
Amgen to Acquire Chemocentryx for $4 Billion In Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine
8:08am
10-Q
2021 Q3
EX-2.7
AMGN
AMGEN Inc.
Quarterly report
3 Nov 21
12:00am
8-K
EX-2.1
AMGN
AMGEN Inc.
4 Mar 21
Amgen to Acquire Five Prime Therapeutics for Acquisition Includes Bemarituzumab, A Phase 3 Ready, First-In-Class Program For Gastric Cancer, the Third Leading Cause of Cancer Mortality Worldwide
8:39am
8-K
EX-2.1
3r4owdbl
26 Aug 19
Amgen to Acquire Otezla® for $13.4 Billion In Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits
10:31am
8-K
EX-2.2
o2y7o7gg10eb
26 Aug 19
Amgen to Acquire Otezla® for $13.4 Billion In Cash, or Approximately $11.2 Billion Net of Anticipated Future Cash Tax Benefits
10:31am
SC TO-C
EX-2.1
emlzfme
26 Aug 13
Information about tender offer
12:00am
8-K
EX-2.1
b077wz8 9n3
26 Aug 13
Amgen to Acquire Onyx Pharmaceuticals
12:00am
8-K
EX-2.1
usoaxssber3jx
30 Apr 12
Amgen to Acquire Mustafa Nevzat, a Leading
12:00am
SC TO-C
EX-2.1
k2jew1
26 Jan 12
Information about tender offer
12:00am
8-K
EX-2.1
fj5cgvodetp2lq
26 Jan 12
Tender and Support Agreement
12:00am
8-K
EX-2.1
7tsk 9zlhrit
2 Oct 06
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
k6fbq23a369t
15 Dec 05
Entry into a Material Definitive Agreement
12:00am
8-K
EX-2.1
mg1 luk05xnc1kau7i
29 Mar 04
Other events
12:00am
POS AM
EX-2.2
cia xbmz0h
15 Jul 02
Prospectus update (post-effective amendment)
12:00am